These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
608 related articles for article (PubMed ID: 13725917)
41. Vaccination against poliomyelitis in Poland with types 1 and 3 attenuated viruses of Koprowski. 1. Virological studies of the vaccine strains and serological studies of the vaccinated population. PRZESMYCKI F; DOBROWOLSKA H; MIRSKI B; WIOR H; STANCZYK R; ZALESKA H Bull World Health Organ; 1962; 26(6):733-43. PubMed ID: 14489069 [TBL] [Abstract][Full Text] [Related]
42. Paralysis after oral poliomyelitis vaccine. HINTON GG; DUNCAN IB; RATHBUN JC Can Med Assoc J; 1962 Oct; 87(17):915-6. PubMed ID: 13954690 [No Abstract] [Full Text] [Related]
43. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals. Mao Q; Wang Y; Shao J; Ying Z; Gao F; Yao X; Li C; Ye Q; Xu M; Li R; Zhu F; Liang Z Hum Vaccin Immunother; 2015; 11(11):2723-33. PubMed ID: 25715318 [TBL] [Abstract][Full Text] [Related]
44. [SEROLOGICAL SURVEY OF CHILDREN FOR ANTIBODIES TO POLIOMYELITIS VIRUSES IN MOSCOW IN 1962]. VOROSHILOVA MK; TARANOVA GP; EMELIANENKOVA VP; SHCHEGLOVA AP; KAPLAN SB Vopr Virusol; 1963; 29():404-9. PubMed ID: 14071275 [No Abstract] [Full Text] [Related]
45. GENETIC MARKERS OF POLIOVIRUS STRAINS ISOLATED FROM PARALYTIC PATIENTS PRIOR TO AND AFTER SABIN VACCINATION PROGRAMS. I. STUDIES ON TYPE 1 STRAINS. FURESZ J; ARMSTRONG RE; YAROSH W; NAGLER FP Am J Hyg; 1964 Jul; 80():45-54. PubMed ID: 14192769 [No Abstract] [Full Text] [Related]
46. Detecting poliovirus in vaccine lots used in Idaho in 1955. EKLUND CM; HADLOW WJ; PICKENS EG; GERLOFF RK Public Health Rep (1896); 1959 Jan; 74(1):60-6. PubMed ID: 13623976 [No Abstract] [Full Text] [Related]
47. The polio eradication effort has been a great success--let's finish it and replace it with something even better. Kimman TG; Boot H Lancet Infect Dis; 2006 Oct; 6(10):675-8. PubMed ID: 17008176 [TBL] [Abstract][Full Text] [Related]
48. Complementfixing antigens of living and inactivated poliovirus. I. Complement-fixing antibody response of laboratory animals to poliovirus. HARE JD; WARREN J Am J Hyg; 1958 May; 67(3):350-66. PubMed ID: 13533408 [No Abstract] [Full Text] [Related]
49. Excretion of attenuated polioviruses in children vaccinated with live oral poliovirus vaccine. Kucharská Z; Srámová H; Zdrazílek J J Hyg Epidemiol Microbiol Immunol; 1982; 26(1):74-82. PubMed ID: 6282962 [TBL] [Abstract][Full Text] [Related]
50. THE PROTECTIVE EFFECT OF SALK VACCINE DURING AN EPIDEMIC OF POLIOMYELITIS, BRITISH COLUMBIA, 1959-1960. LARSEN AA Can J Public Health; 1965 Feb; 56():47-50. PubMed ID: 14281078 [No Abstract] [Full Text] [Related]
51. Epidemiology of poliomyelitis--options and update. Dutta A Vaccine; 2008 Oct; 26(45):5767-73. PubMed ID: 18755232 [TBL] [Abstract][Full Text] [Related]
52. ANTIGENIC ANALYSIS OF TYPE I POLIOVIRUS ANALYSIS OF THE RECENT EPIDEMIC STRAINS IN JAPAN. TOYOSHIMA K; OTSU K; YAMADA T; MORIMOTO Y; KUNITA N Biken J; 1964 Apr; 7():21-35. PubMed ID: 14222183 [No Abstract] [Full Text] [Related]
53. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Ghendon Y; Robertson SE Bull World Health Organ; 1994; 72(6):973-83. PubMed ID: 7867144 [TBL] [Abstract][Full Text] [Related]
54. A phase contrast microprecipitin test with poliovirus antigens. I. Properties of the antigens and antibodies and optimum conditions for reaction. EGGERS HJ; SABIN AB Arch Gesamte Virusforsch; 1961; 11():120-51. PubMed ID: 13725916 [No Abstract] [Full Text] [Related]
55. Neutralizing capacity of poliovirus type 3 antibodies tested against 5 different intratypic variants of poliovirus type 3. A comparative study in children immunized with live, inactivated, or both types of poliovirus vaccines. Böttiger M Arch Gesamte Virusforsch; 1971; 35(2):251-5. PubMed ID: 4332939 [No Abstract] [Full Text] [Related]
56. Interference patterns encountered when using attenuated poliovirus vaccines. HALE JH; LEE LH; GARDNER PS Br Med J; 1961 Sep; 2(5254):728-32. PubMed ID: 13710702 [No Abstract] [Full Text] [Related]
57. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Pliaka V; Kyriakopoulou Z; Markoulatos P Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246 [TBL] [Abstract][Full Text] [Related]
58. [Virological surveys of the presence of enteroviruses in waste water. I. Incidence of polioviruses in Prague at the end of 1968 and in 1969]. Zdrazílek J; Zácek K; Chvapil J; Mikesová V; Pokorná L; Tomanová V; Trauc J; Vrábková J Cesk Epidemiol Mikrobiol Imunol; 1971 Mar; 20(2):67-72. PubMed ID: 4324445 [No Abstract] [Full Text] [Related]
59. [ISOLATED FACIAL PARALYSIS IN CHILDHOOD. II. CLINICAL AND ETIOLOGICAL ASPECTS]. PANERO C; BERDONDINI I Riv Clin Pediatr; 1964 Jan; 73():35-56. PubMed ID: 14201993 [No Abstract] [Full Text] [Related]
60. [SEROLOGICAL AND VIROLOGICAL STUDIES ON THE VACCINATION OF ATTENUATED LIVE POLIOVIRUS VACCINE]. KIDA T; HARADA Y; TOMITA Y Kumamoto Igakkai Zasshi; 1963 Sep; 37():543-53 CO. PubMed ID: 14090753 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]